Funded by: European Commission
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF) (Spain), DEBRECENI EGYETEM (Hungary), ODENSE UNIVERSITETSHOSPITAL (Denmark), KOBENHAVNS UNIVERSITET (Denmark), EUROPEAN MOLECULAR BIOLOGY LABORATORY (Germany), COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France), MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV (Germany), Vaiomer (France), INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (France), UNIVERSITAETSKLINIKUM BONN (Germany), KATHOLIEKE UNIVERSITEIT LEUVEN (Belgium), ACADEMISCH ZIEKENHUIS LEIDEN (Netherlands), UNIVERSITAT DE BARCELONA (Spain), BIOBYTE SOLUTIONS GMBH (Germany), FUNDACIÓ INSTITUT CATALÀ DE NANOCIÈNCIA I NANOTECNOLOGIA (Spain), UNIVERSITY COLLEGE LONDON (UK), UNIVERSITETET I OSLO (Norway), EUROPEAN LIVER PATIENTS ASSOCIATION (Belgium), Concentris Research Management GmbH (Germany), KING’S COLLEGE LONDON (UK), FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA (Spain), EUROPEAN ASSOCIATION FOR THE STUDYOF THE LIVER (Switzerland)
Decompensation of liver cirrhosis and progression towards acute-on-chronic liver failure (ACLF) causes 1.2 million deaths/ year. Microbiome is causally involved in cirrhosis progression and is for drugs the first interaction point with the patients. Drugs can alter the microbiome leading to unwanted effects or even facilitating their effects, but the microbiome metabolizes the drugs, shapes their effects and possibly determines the host response to drugs. As each person carries an individual microbiome, insight in these processes should help stratify or even personalize patient health care and treatment. The aims of MICROB-PREDICT are 1) to better understand the role of microbiome and the gut-liver-axis interactome with respect to microbiome functionalities, 2) to identify and validate microbiome-based biomarkers and signatures for personalized prediction of decompensation and ACLF, and response to treatment, 3) to design three new tests as easy-touse tools and point-of-care, smartphone-connected nanobiosensors, and 4) to validate them in a randomized controlled trial. MICROB-PREDICT will assemble existing data and samples from major microbiome initiatives in hepatology (12 international studies, >10,000 patients), and enrich them with holistic and in-depth analysis using cutting-edge multi-omics technologies of host and microbiome from different body sites in samples of >1,000 patients collected in a longitudinal manner with sequential visits and controlling for confounders. MICROB-PREDICT results will foster more accurate, personalized risk stratification and significant steps towards personalized treatment of decompensated cirrhosis and ACLF. World-leading microbiome specialists, technology leaders and clinical experts make this a programme of scientific excellence; patient organisations (ELPA) and the European Association for the study of the Liver (EASL) will channel our results into a powerful dissemination, communication and exploitation programme.